Preclinical Toxicology and Biodistribution Studies of Recombinant Adeno-Associated Virus 1 Human Acid α-Glucosidase
Thomas J. Conlon(Adelson Foundation), Barry J. Byrne(University of Florida), Travis Cossette(University of Florida), Kirsten Erger(University of Florida), Lynn A. Combee(University of Florida), Stacy Porvasnik(University of Florida), Cheryl Roberts(University of Florida), Corinne R. Abernathy(University of Florida), Saleem Islam(University of Florida), Nathalie Clément(University of Florida), Denise Cloutier(University of Florida), Jeffry S. Kelley(University of Florida)
Cited by 21
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322